EC fines Teva €60.5m over pay-for-delay deal
27-11-2020
FTC’s $448m AbbVie win overturned
02-10-2020
Ascannio / Shutterstock.com
Twenty US states, the US Federal Trade Commission (FTC), and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
USFTC, AbbVie, Humira, immunosuppressant, biosimilar, patent litigation, reverse payments, Supreme Court, biologic, settlement
